Paragon 28 (Paragon 28) Debt-to-Revenue : 0.46 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Paragon 28 Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Paragon 28's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.6 Mil. Paragon 28's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $109.8 Mil. Paragon 28's annualized Revenue for the quarter that ended in Dec. 2023 was $242.2 Mil. Paragon 28's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.46.

Paragon 28 Debt-to-Revenue Historical Data

The historical data trend for Paragon 28's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paragon 28 Debt-to-Revenue Chart

Paragon 28 Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

0.19

0.06

0.05

0.24

0.51

Paragon 28 Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial											0.21	0.21	0.21	0.20	0.46

Competitive Comparison of Paragon 28's Debt-to-Revenue

For the Medical Devices subindustry, Paragon 28's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Paragon 28's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Paragon 28's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Paragon 28's Debt-to-Revenue falls into.

Paragon 28 Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Paragon 28's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.64	+	109.799)	/	216.389
	=	0.51

Paragon 28's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.64	+	109.799)	/	242.244
	=	0.46

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

Paragon 28 Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Paragon 28's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Paragon 28 (Paragon 28) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Paragon 28 Inc (NYSE:FNA) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

7GQ:Germany

Address

14445 Grasslands Drive, Englewood, CO, USA, 80112

Website

https://www.paragon28.com

Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, charcot, fracture fixation, hallux valgus, hammertoe, and flatfoot.

Executives

Albert Dacosta	director, officer: See Remarks	C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
Robert S Mccormack	officer: See Remarks	C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Thomas P Schnettler	director	800 NICOLLET MALL, J1012057, MINNEAPOLIS MN 55402-7020
Kristina Wright	director	C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
B. Ag Bird	10 percent owner	BAHNHOFSTRASSE 7, ZUG V8 CH-6300
Mvm Partners, Llc	10 percent owner	OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Matthew Jarboe	officer: Chief Commercial Officer	C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
Partners Llp Mvm	10 percent owner	30 ST. GEORGE STREET, LONDON X0 W1S SFH
Jonathan I Friedman	officer: General Counsel	DENTSPLY SIRONA INC., 30-30 47TH AVENUE, SUITE 500, LONG ISLAND CITY NY 11101
Lee Rosenthal	10 percent owner	C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
Quentin S. Blackford	director	7475 LUSK BLVD., SAN DIEGO CA 92121
Frank S. Bono	officer: Chief Technology Officer	5677 AIRLINE ROAD, ARLINGTON TN 38002
Jason Allan Edie	officer: Chief Technology Officer	C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
Erik E Mickelson	officer: Chief Accounting Officer	C/O PARAGON 28, INC., 14445 GRASSLANDS DRIVE, ENGLEWOOD CO 80112
Meghan Scanlon	director	C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752